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Abstract
Activated B-cell lymphoma (ABC), one of the three subtypes of Diffuse Large B-cell Lymphoma (DLBCL) has the worst
survival rate after upfront chemotherapy and is characterized by constitutively activated NFkB. We therefore studied the
role of NFkB In a cohort of clinical DLBCL samples and ABC cell lines. In our clinical tissue microarray cohort of DLBCL
samples, p-IkBa was detected in 38.3% of ABC DLBCL and was an independent prognostic marker for poor survival. In vitro,
we found that Thymoquinone (TQ), a natural compound isolated from Nigella sativa caused release of ROS in ABC cells. TQ-
mediated release of ROS in turn inhibited NFkB activity by dephosphorylating IkBa and decreased translocation of p65
subunit of NFkB in the nuclear compartment in ABC cell lines. This led to inhibition of cell viability and induction of
mitochondrial dependent apoptosis in ABC-DLBCL cell lines. Additionally, TQ treatment also caused up-regulation of death
receptor 5 (DR5), however, up-regulation of DR5 did not play a role in TQ-induced apoptosis. Finally, combination of sub-
optimal doses of TQ and TRAIL induced efficient apoptosis in ABC-DLBCL cell lines. These data show that p-IkBa can be used
as a prognostic marker and target for therapy in this aggressive sub-type of DLBCL and TQ may play an important role in the
management of DLBCL in the future.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of lymphoma accounting for 30–40% of all lymphomas. The
treatment of DLBCL has been revolutionized over the last decade
with the addition of Rituximab, an anti-CD20 monoclonal
antibody in combination with CHOP [1], however, this disease
still remains refractory to treatment in 50% of cases [2]. Gene
expression studies performed have been able to identify three
distinct groups of DLBCL based on their origin at different stages
of differentiation[3]. Of the three groups of DLBCL, activated B
cell lymphoma (ABC) tends to have a poor 5 year survival rate of
34%[4,5] as compared to germinal center B-cell (59%) and
primary mediastinal B-cell lymphoma (PMBCL) (64%). The
hallmark of ABC subtype of DLBCL is activation of the NFkB
survival pathway that allows the malignant cell towards plasma cell
differentiation [6]. Activation of NFkB pathway occurs when
IkBa, an inhibitor of NFkB is degraded by either proteasomal
degradation or ubiquitination allowing NFkB to enter the nucleus
and exerts its transcriptional activation on growth factors such as
interleukins and pro-survival and anti-apoptotic proteins such as
Bcl-2, Bcl-Xl, XIAP and Survivin[7,8,9].
Thymoquinone (TQ) is a naturally occurring compound that is
extracted from Nigella sativa Linn [10]. TQ has been shown to
possess anti-inflammatory, anti-oxidant and anti-neoplastic activ-
ity [11]. TQ has been shown to possess antitumor activities against
a broad spectrum of cancer cells, including colon, ovarian, and
myeloblastic leukemia[11,12,13]. The exact mode of action of TQ
is not known, however, it has been shown that TQ induces its anti-
tumor effect via release of reactive oxygen species (ROS)[14].
Recently, it has been shown that TQ enhances the effect of
doxorubicin and oxaliplatin in various cancers[15,16].
In the present study, we first examined the expression of p-IkBa
and its association with clinical and pathological parameters in a
cohort of ABC-DLBCL clinical samples in a tissue microarray
format. We next investigated the role of NFkB pathway on cell
survival in ABC cell lines. We also demonstrated the mode of
action of TQ for induction of apoptosis and found that TQ
inactivated the NFkB pathway via release of ROS. Finally, in this
study, we evaluate the combination therapy of TQ and TRAIL in
induction of apoptosis in ABC cell lines.
Materials and Methods
Ethics Statement
The Institutional Review Board (IRB) and Research Advisory
Council (RAC) of KFSHRC approved this study: RAC #
2060008. A waiver of consent was obtained from IRB and ethics
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committee as this study was performed on archival samples and
the samples were analyzed anonymously.
Patient Samples and Tissue microarray
Two hundred and thirty one cases of de novo DLBCL diagnosed
at the King Faisal Specialist Hospital and Research Centre
(KFSHRC) and reclassified according to the WHO criteria[17]
were included in this study. Archival paraffin blocks were obtained
and tissue microarrays (TMA) were constructed as described
previously[18]. The institutional review board (IRB) of KFSHRC
approved the study (Project RAC# 2060008).
Immunohistochemistry (IHC)
TMA slides were processed and stained manually. The IHC
protocol was followed as mentioned before[19]. Primary antibodies
used, their dilutions, and cutoff levels are listed in Table S1. Each
TMA spot was assigned an intensity score from 0–3(I0, I1–3) and
proportion of tumor staining for that intensity was recorded as 5%
increments from a range of 0–100(P0, P1–3). A final H score (range
0–300) was obtained by adding the sum of scores obtained for each
intensity(I) and proportion(P) of area stained (H score = I16P1+I26
P2+I36P3). X-tile plots were constructed for assessment of
biomarker and optimization of cut off points based on outcome as
described earlier[19,20].
Cell lines
The human ABC cell lines HBL-1, OCI-LY3, RIVA and
SUDHL2 were a kind gift from Dr Laura Pasqualucci Institute for
Cancer Genetics and the Herbert Irving Comprehensive Cancer
Center, Columbia University, New York, USA and have been
used previously[21,22]. The cell lines were cultured in IMDM
supplemented with 20% (v/v) fetal bovine serum (FBS), 100 U/ml
penicillin, 100 U/ml streptomycin at 37uC in a humidified
atmosphere containing 5% CO2. All the experiments were
performed in either RPMI-1640 or IMDM containing 5% serum.
All the cell lines were authenticated in house using human
identifiler multiplex kit (Life Technologies, New York, NY).
Reagents and antibodies
Thymoquinone (TQ), N-acetyl cysteine (NAC) and Bax 6A7
monoclonal antibody were purchased from Sigma Chemical Co
(St. Louis, MO, USA). zVAD-fmk were purchased from
Calbiochem (San Diego, CA, USA). Antibodies against caspases-
8, -9, DR5, Bcl-Xl, and cleaved caspase-3 were purchased from
Cell Signaling Technologies (Beverly, MA, USA). Cytochrome c,
p65, p-IkBa, IkBa, caspase-3, and PARP antibodies were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Survivn, cIAP-1 and cIAP2 antibodies were purchased
from R&D. Beta-actin and XIAP antibodies were purchased from
Abcam (Cambridge, England). Annexin V was purchased from
Molecular Probes (Eugene OR, USA). Apoptotic DNA-ladder kit
was obtained from Roche (Penzberg, Germany).
MTT assays
MTT assay was performed as described earlier [23]. Briefly, 104
cells were incubated in triplicate with indicated doses of TQ for
24 hour at 37uC. Thereafter, 25 mL MTT solution (5 mg/ml in
water) was added and after 24 hour incubation at 37uC, 0.1 mL
extraction buffer (20% SDS) was added and optical density (OD)
at 590 nm was measured.
Annexin V staining
ABC cell lines were treated with different concentrations of TQ
as described in the legends. Cells were harvested and the
percentage apoptosis was measured by flow cytometry after
staining with flourescein-conjugated annexin-V and propidium
iodide (PI) (Molecular probes, Eugene, OR) as described
previously[24].
Cell lysis and Immunoblotting
Cells were treated with TQ as described in the legends and lysed
as previously described[25]. Immunoblotting was performed with
different antibodies and visualized by an enhanced chemilumi-
nescence (ECL, Amersham, Illinois, USA) method.
Detection of Bax conformational changes
This assay was performed as described previously[26]. Briefly,
following treatment with indicated reagents for various time
points, cells were lysed with Chaps lysis buffer and 500 mg of total
protein was incubated with 2 mg of anti-Bax 6A7 monoclonal
antibody and 25 ml of protein G-beads and incubated at 4uC
overnight. Following washes in lysis buffer, samples were separated
by SDS-PAGE, transferred and immunoblotted using N20 Bax
polyclonal antibody.
Assay for cytochrome c release
Release of cytochrome c from mitochondria was assayed as
described earlier [21]. Following treatment, cells were lysed and
mitochondrial and cytosolic extracts were prepared, immuno-
botted and probed with cytochrome c antibody.
Measurement of mitochondrial potential using the JC-1
(5, 59, 6, 69-teterachloro-1, 19, 3,39-
tetraethylbenzimidazolylcarbocyanine iodide) assay
16106 cells were treated with TQ for 24 hours. Cells were
washed with PBS and suspended in mitochondrial incubation
buffer (Alexis Corporation, Farmingdale, NY, USA) and 10 mM
JCI and mitochondrial membrane potential (% of green and red
aggregates) was determined by flow cytometry as described
previously [21].
Gene Silencing using SiRNA
DR5 SiRNA, AKT siRNA and Scrambled control siRNA were
purchased from Qiagen. p65 siRNA was purchased from Sant
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). For transient
expression, cell lines were transfected by using LipofectAMINE
2000 reagent (Invitrogen, Carlsbad, CA). After incubating the cells
for 6 hrs, the lipid and SiRNA complex was removed and fresh
growth medium was added. Cells were treated 48 hours after
transfection for 24 hours and specific protein levels were
determined by Western Blot analysis with specific antibodies.
Preparation of nuclear extracts for NFkB
Nuclear extracts were prepared according as described previ-
ously[27]. Briefly, 16107 cells were washed with cold PBS and
suspended in 0.4 mL hypotonic lysis buffer containing protease
inhibitors for 30 minutes. The cells were then lysed with 10%
Nonidet P-40.
Measurement of ROS
We used H2DCFDA, a cell permeable fluorescent probe for
detection for ROS release as described earlier [28]. Briefly, 16106
exponentially growing cells were loaded with 10 mM H2DCFDA
for 45 minutes at 37uC and then treated with TQ for various time
Thymoquinone Mediated ROS Release in ABC Cells
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periods in presence of 10 mM NAC. Following incubation, the
cells were washed with PBS and green fluorescence intensity in the
cells was examined by FACS analysis.
Electrophoretic mobility shift assay for NFkB
The single-stranded 39-end biotin-labeled probe containing the
NFkB consensus site 59-AGTTGAGGGGACTTTCCCAGGC-
39, and 39-TCAACTCCCCTGAAAGGGTCCG59 were pur-
chased from Metabion (martinsried, Germany). The biotinylated
oligonucleotides were annealed by denaturing at 90uC for 1 min
and cooled to room temperature for 1 hour. The EMSA binding
reactions were performed by utilizing a LightShift chemilumines-
cent EMSA kit (Pierce, Rockford, IL, USA) as described
previously[27].
Luciferase Reporter Assays
ABC cells were transfected with a b-galactosidase and plasmid
pNFkB-LUC linked to a minimal E1B promoter-luciferase gene
using the Lipofectamine transfection reagent as per manufacturer’s
recommended procedure (Qiagen, Valencia, CA). Forty-eight
hours after transfection, cells were either pre-treated with 10 mM
NAC for 3 hours followed by treatment with 10 mM TQ for
24 hours and luciferase activity was measured using manufactur-
er’s protocol (Promega, Madison, WI). The measured luciferase
activities were normalized for b-galactosidase activity for each
sample.
Statistical Analysis
The JMP 9.0 (SAS Institute Inc., Cary, NC) software package
was used for data analyses. Survival curves were generated using
Kaplan-Meier method, with significance evaluated using the
Mantel-Cox log-rank test. Risk ratio was calculated using the Cox
proportional hazard model in both univariate and multivariate
analyses. Cell line data are presented, as mean 6 SD.
Comparisons between groups were made with the paired Student’s
t-test. Values of p,0.05 were considered statistically significant.
Results
p-IkB expression in DLBCL patients
Activation of NFkB pathway requires prior phosphorylation of
IkBa at Ser32 and Ser34 site for it be a target of ubiquitination
and degradation releasing p50–p65 heterodimer to translocate to
the nucleus [29]. We therefore sought to determine the status of p-
IkBa in clinical samples of ABC-DLBCL. Immunohistochemical
analysis of p-IkB expression was interpretable in 151 DLBCL
spots and p-IkB expression was predominantly seen in the
cytoplasmic compartment. The incidence of p-IkB expression in
all DLBCL cases and in the ABC subgroup was 38.4% (58/151)
and 38.3% (46/120) respectively (Figure 1A). p-IkB expression in
the ABC samples did not correlate with age, gender, IPI and Stage
(Table 1). Interestingly, p-IkB over expressing ABCs showed a
poor outcome (p = 0.0724) of 56.3% as compared to (p= 0.0724)
of 78.1% in ABC with reduced p-IkB expression (Figure 1B).
Using multivariate analysis in ABC subgroup of DLBCL, for IPI
and p-IkB expression, the relative risk was 2.98 for high p-IkB
expression (95%; CI 1.17–8.52; p = 0.0213) and 4.08 for high IPI
group (95% CI 1.61–11.15; p = 0.0030). Thus, p-IkB over
expression was an independent prognostic marker for poor
survival in all ABC subgroup of DLBCL (Table S2).
TQ inhibited constitutively activated NFkB in ABC cell
lines
As NFkB survival pathway has been found to be constitutively
activated in cancers cell lines[27], we were interested in
investigating whether there was constitutive activation of NFkB
in ABC cell lines. As shown in Figure 2A, constitutively activated
NFkB was detected in all ABC cell lines as assessed by EMSA.
Next, we sought to determine whether TQ treatment suppressed
constitutive activation of NFkB in ABC cell lines. HBL-1 and
RIVA cell line were treated with 5 and 10 mM TQ for 24 hours
and nuclear extracts were analyzed with EMSA. TQ treatment
decreased translocation of p65 in nuclear compartment in a dose
dependent manner in both the cell lines (Figure 2B). We also
examined the phosphorylation status of p65 in the nuclear
compartment following treatment with TQ and found constitutive
activation of p65 in ABC cells and TQ treatment inactivated
phosphorylation of p65 in a dose dependent manner (Figure S1).
We next investigated whether TQ treatment inactivated IkBa
phosphorylation. As shown in Figure 2C, untreated samples
demonstrated constitutive activation of Ser32-phosphorylated
IkBa and treatment with TQ de-phosphorylated IkBa. P65
subunit of NFkB has been shown to transcriptionally up-regulate
the expression of various anti-apoptotic and pro-survival gene[30].
We were therefore interested to determine whether TQ treatment
could down-regulated expression of down-stream targets of p65.
Figure 1. Tissue microarray based immunohistochemical
analysis of p-IkB expression in DLBCL patients: DLBCL array
spot showing high expression of p-IkB (A) and low expression
of p-IkB (B). 206/0.70 objective on an Olympus BX 51 microscope.
(Olympus America Inc, Center Valley, PA, USA. with the inset showing a
4060.85 aperture magnified view of the same. (C). Impact of p-IkB
expression on prognosis in ABC patients. In patients with activated B
cell phenotype(ABC) subgroup, p-IkB over expression showed a poor
overall survival of 56.3% at 5 years as compared to 78.2% with low p-IkB
expression (p = 0.0724).
doi:10.1371/journal.pone.0060540.g001
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As shown in Figure 2D, TQ treatment down-regulated the
expression of IkBa, Bcl-2, Bcl-Xl, XIAP and Survivin in a dose
dependent manner in both the cell lines tested. This data was
further confirmed by targeting ABC cell lines with siRNA against
p65. As shown in Figure 2E, similar response was observed
confirming the specificity of TQ in the treatment of ABC.
TQ causes Reactive Oxygen Species (ROS) release in ABC
cells
TQ has been previously shown to cause release of ROS in
cancer [13,14]. To investigate this, we treated ABC cell lines with
10 mM TQ for various time periods and cells were stained with
H2DCFDA, a detector of ROS release and analyzed by flow
cytometry. Both HBL-1 and RIVA cell line demonstrated release
of ROS starting as early as 2 hours, peaking between 4 and
8 hours and slowly tapering up to 24 hours (Figure 3A). To
confirm ROS release, we pre-treated HBL-1 and RIVA cells with
N-acetyl cysteine (NAC), a scavenger of ROS release for 3 hours
and then treated the cells with 10 mM TQ for up to 8 hours. As
shown in Figure 3B, ROS release was blocked in cells pre-treated
with NAC. We next examined whether TQ treatment can repress
constitutive active NFkB gene expression in reporter assays. RIVA
cells were transiently transfected with NFkB reporter construct for
48 hours and then treatment with TQ for 24 hours and luciferase
activity was determined. As shown in Figure 3C, constitutive
NFkB luciferase activity was seen in untreated cells while TQ
treatment abrogated the constitutive NFkB-reporter activity.
Interestingly, NAC pre-treatment of RIVA prevented TQ-induced
abrogation of luciferase activity. Finally, to confirm that TQ-
induced inactivation of NFkB is related to ROS release, we pre-
treated HBL-1 and RIVA cells with NAC for three hours and then
treated with 10 mM TQ for 24 hours. As shown in Figure 3D,
NAC pre-treatment blocked TQ-induced down-regulation of
NFkB targets; IkBa, Bcl-2 and Survivin confirming the mode of
action of TQ being ROS release in ABC cells. Finally, to
determine the mode of generation of ROS by TQ, we pre-treated
ABC cell lines with either catalase, superoxide dismutase and
NAC for three hours followed by treatment with 10 mM TQ for
24 hours and examined the cells for apoptosis by flow cytometry.
As shown in Figure S2, catalase and SOD partially blocked TQ-
induced apoptosis, however when both the inhibitors were used in
combination, there was efficient inhibition of apoptosis. These
data suggest that TQ generates superoxide anion (O2-) and
hydrogen peroxide (H2O2) radicals.
TQ-induced activation of mitochondrial apoptotic
pathway in ABC cells
The anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-
Xl are transcriptional targets of NFkB and TQ treatment of ABC
cells led to down-regulation of these proteins (Figure 2D). This
leads to conformational changes in the pro-apoptotic protein; Bax.
To confirm this, we treated HBL-1 cell line with 10 mM TQ for
various time periods and lysed with 1.0% Chaps lysis buffer;
lysates were immuno-precipitated with BAX 6A7 antibody that
recognizes only the conformationally changed Bax protein. The
detergent Chaps has been shown to retain Bax in its native
conformation [31]. As shown in Figure 4A, expression of
conformationally changed Bax increased in 8 and 16 hours after
treatment with 10 mM TQ. To assess whether conformational
changes in Bax protein is due to TQ-induced ROS release or
activation of caspases, we pre-treated HBL-1 cells with either
10 mM NAC or 80 mM zVAD-fmk, an universal inhibitor of
caspases for 3 hours followed by treatment with 10 mM TQ for
8 hours. NAC pre-treatment blocked TQ-induced conformational
changes of Bax protein while zVAD-fmk pre-treatment did not
alter changes in Bax protein (Figure 4B). This data clearly
suggested that ROS release secondary to TQ treatment induced
Bax conformational changes in ABC cell lines.
Once Bax is conformationally changed, it translocates to the
mitochondrial membrane and causes changes in the mitochondrial
Table 1. Correlation of p-IkB expression with clinico-
pathological parameters in ABC subtypes of DLBCL samples.
Total High Low P value
No. % No. % No. %
No. of Patients$ 120 46 38.3 74 61.7
Age (all pts)
#50 73 60.8 25 34.2 48 65.8 0.2523
.50 47 39.2 21 44.7 26 55.3
Sex (all pts)
Female 47 39.2 20 42.6 27 57.4 0.4464
Male 73 60.8 26 35.6 47 64.4
Perf. Status (IPI)
0–2 54 60.7 19 35.2 35 64.8 0.1293
3–4 35 39.3 18 51.4 17 48.6
Stage (IPI)
I–II 47 52.8 18 38.3 29 61.7 0.5072
III–IV 42 47.2 19 45.2 23 54.8
Extranodal (IPI)
.1 site 41 46.1 12 29.3 29 70.7 0.0283
1 site 48 53.9 25 52.1 23 47.9
LDH (IPI)
Normal (,480) 36 40.4 16 44.4 20 55.6 0.6508
High (.480) 53 59.6 21 39.6 32 60.4
IPI Group@
Low–Low Inter 58 65.2 24 41.4 34 58.6 0.9596
High Inter–High 31 34.8 13 41.9 18 58.1
BCL-XL
Above 230 27 23.5 13 48.1 14 51.9 0.2308
Below= 2300 88 76.5 31 35.2 57 64.8
XIAP
Above 150 67 56.3 28 41.8 39 58.2 0.4243
Below= 150 52 43.7 18 34.6 34 65.4
NFKB (Sc 372)
Above 0 38 34.6 12 31.6 26 68.4 0.1868
Below= 0 72 65.4 32 44.4 40 55.6
5-Year Overall
Survival
56.3 78.1 0.0724
@IPI & Stage information was available only in 89 patients.ˆGC vs. ABC Germinal
Centre (GC) versus Activated B Cell (ABC) phenotype.$Of the 201 Diffuse Large B
cell lymphomas, p-IkB results were available in 151 cases and the remaining 50
spots were non informative. Analysis failure for these IHC markers was
attributed to missing or non representative spots. Of these 151 TMA spots with
available p-IkB data, range of non available spots for rest of the IHC markers
ranged from 1 spot for XIAP to 18 spots for XIAP. The remaining cases were
considered for correlation analysis.
doi:10.1371/journal.pone.0060540.t001
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membrane potential leading to release of cytochrome c into
cytosole. We therefore treated ABC cell lines with 5 and 10 mM
TQ for 24 hours and stained the cells with JC1 dye and analyzed
the cells by flow cytometry. As shown in Figure 4C, TQ treatment
resulted in loss of mitochondrial membrane potential as measured
by JC1 stained green florescence depicting apoptotic cells.
Additionally, changes in mitochondrial membrane potential led
to release of cytochrome c into cytosole from the mitochondria
suggesting that the mitochondrial pathway was being activated
following TQ treatment (Figure 4D and E).
Figure 2. Effect of TQ on constitutive nuclear NFkB in ABC cells. (A) Constitutive expression of NFkB in ABC cells. Nuclear extracts were
prepared and electrophoretic mobility shift assay (EMSA) was performed as described in Materials and Methods. (B) TQ inhibits constitutive
nuclear NFkB in ABC cells. HBL-1 and RIVA cells were treated with indicated doses of TQ for 24 hours. Nuclear extracts were prepared and EMSA
was performed to determine the expression of p65 in the nuclear compartment. (C) TQ inactivates IkBa in ABC cell lines. HBL1 and RIVA cell lines
were treated with 5 and 10 mM TQ for 24 hours. Cells were lysed and equal amounts of proteins were separated by SDS-PAGE, transferred to PVDF
membrane, and immunoblotted with antibodies against p-IkBa and beta-actin. (D) TQ causes down-regulation of expression of down-stream
targets of p65. HBL-1 and RIVA cells were treated with 5 and 10 mM TQ for 24 hours. Cells were lysed and equal amounts of proteins were separated
by SDS-PAGE, transferred to PVDF membrane, and immunoblotted with antibodies against IkBa, Bcl-2, Bcl-Xl, XIAP, Survivin and actin as indicated. (E)
Transcriptional down-regulation of p65 causes decreased expression of p65 targets in ABC cells. HBL-1 and RIVA cells were transfected
with siRNA against p65 for 48 hours. Following transfection, cells were lysed and equal amounts of proteins were separated by SDS-PAGE, transferred
to PVDF membrane, and immunoblotted with antibodies against IkBa, Bcl-2, Bcl-Xl, XIAP, Survivin and Beta-actin.
doi:10.1371/journal.pone.0060540.g002
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Activation of the mitochondrial apoptotic pathway leads to
activation and cleavage of caspases-9 and -3 in response to various
apoptotic-inducing agents [21]. Treatment of ABC cell lines with
TQ also activated and cleaved caspases-9 and -3 and PARP in a
dose dependent manner (Figure 5A). In order to determine
whether activation and cleavage of caspases is dependent on ROS
Figure 3. Thymoquinone-induced generation of ROS in ABC cells. (A) Thymoquinone increases ROS generation in ABC cells. HBL-1
and RIVA cells were incubated in the absence or presence of 10 mM TQ for indicated time periods. After washing with PBS, cells were incubated with
10 mM H2DCFDA and incubated in the dark for 30 minutes at 37uC as described in material and method. Cells were washed in PBS, re-suspended in
PBS and analyzed by flow cytometry. (B) NAC prevents TQ-induced ROS release in ABC cells. HBL-1 and RIVA cell lines were pre-treated with
10 mM NAC for 21hours followed by treatment with 10 mM TQ for various time periods. Cells were washed in PBS and incubated with 10 mM
H2DCFDA and incubated in the dark for 30 minutes at 37uC. Cells were washed in PBS, re-suspended in PBS and analyzed by flow cytometry. Bar
graph displays the mean +/2 SD (standard deviation) of three independent experiments, * p,0.05, statistically significant (Students t-test). (C) (C)
NFkB activity is down-regulated by TQ as measured by Luciferase assay. RIVA cells were transiently transfected with p65-LUC plasmid for
48 hours. After transfection, RIVA cells were divided into three groups; one group was left untreated as control, the second group was treated with
10 mM TQ for 24 hours and third group was pretreated with 10 mM NAC for 3 hours followed by treatment with 10 mM TQ for 24 hours. After
24 hours, cells were lysed in luciferase lysis buffer and luciferase activity was measured. pCDNA plasmid was used as transfection control and b-
galactosidase was used to normalize the transfection efficiency. (D) NAC prevents TQ-induced down-regulation of targets of p65. HBL-1 and
RIVA cells were pre-treated with 10 mM NAC for three hours followed by treatment with 10 mM TQ for 24 hours. Cells were lysed and proteins were
immunoblotted with antibodies against IkBa, Bcl-2 and Survivin.
doi:10.1371/journal.pone.0060540.g003
Thymoquinone Mediated ROS Release in ABC Cells
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release, we pre-treated HBL-1 cell line with either 10 mM NAC or
80 mM zVAD-fmk for 3 hours followed by treatment with TQ for
24 hours. As shown in Figure 5B, both NAC as well as zVAD-fmk
pre-treatment were able to block TQ-induced activation of
caspases-9, -3 and cleavage of PARP.
We also wanted to determine whether TQ treatment could
inhibit cell viability and induce apoptosis in ABC cell lines. We
Figure 4. TQ-induced mitochondrial signaling pathway in ABC cells. (A) TQ treatment causes Bax conformational changes in ABC cells. After
treating with 10 mM TQ for indicated time periods, HBL-1 cells were lysed and immuno-precipitated with anti-Bax 6A7 antibody for detection of
conformationally changed Bax protein. In addition, the total cell lysates were immuno-blotted with specific anti-Bax polyclonal antibody. (B) NAC
prevents TQ-induced Bax conformational changes in ABC cells. HBL-1 cells were pre-treated with either, 10 mM NAC and 80 mM z-VAD/fmk for
3 hours and subsequently treated with 10 mM TQ for 8 hours. Cells were lysed and immunoprecipitated with anti-Bax 6A7 antibody and proteins
were immunoblotted with Bax rabbit polyclonal antibody. (C) TQ treatment causes change in mitochondrial membrane potential in ABC cells. ABC
cells were treated with and without 5 and 10 mM TQ for 24 hours. Live cells with intact mitochondrial membrane potential and dead cells with lost
mitochondrial membrane potential was measured by JC-1 staining and analyzed by flow cytometry as described in Materials and Methods. Bar graph
displays the mean +/2 SD (standard deviation) of three independent experiments, * p,0.05, statistically significant (Students t-test). (D) TQ treatment
causes release of cytochrome c from mitochondria into cytosole. HBL-1 and RIVA cells were treated with 5 and 10 mM TQ for 24 hours. Mitochondrial
free cytosolic fractions were isolated and immunoblotted with antibody against cytochrome c and Beta-actin.
doi:10.1371/journal.pone.0060540.g004
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treated ABC cell lines with incremental doses of TQ for 24 hours
and analyzed the cells for cell viability by MTT assay. As shown in
Figure 5C, there was a dose dependent inhibition of cell viability in
all the ABC cell lines tested following treatment with TQ. We were
also able to detect dose dependent apoptosis in ABC cell lines
treated with increasing doses of TQ for 24 hours (Figure 5D).
These doses have been previously shown to be non-toxic to
peripheral blood mononuclear cells isolated from normal healthy
individuals[14]. These data clearly suggested that TQ activated
the mitochondrial apoptotic pathway to induce apoptosis in ABC
cells.
TQ-induced ROS generation causes up-regulation of
Death Receptor 5 (DR5)
Recent studies have shown that DR5 expression is up-regulated
by ROS generated by TQ[14]. In view of these findings, we
sought to determine whether TQ-generated free radicals modulate
the expression of DR5 in ABC cells. We first treated HBL-1 and
RIVA cell lines with 5 mM TQ for indicated time periods and
expression of DR5 was determined by immune-blotting. DR5 was
found to be up-regulated within 8 hours of TQ treatment in both
the cell lines (Figure 6A). We next sought to determine whether
ROS release secondary to TQ treatment led to up-regulation of
Figure 5. TQ-induced caspases dependent apoptosis in ABC cells. (A) TQ treatment causes activation and cleavage of caspases in ABC cells.
HBL-1 and RIVA cells were treated with and without 5 and 10 mM TQ for 24 hours. Cells were lysed and equal amounts of proteins were
immunoblotted with antibodies against caspase-9, caspase-3, PARP and Beta-actin. (B) TQ-induced caspases activation and cleavage is blocked by
NAC and caspases inhibitor. HBL-1 cells were pretreated with either 10 mM NAC or 80 mM z-VAD for 3 hours and subsequently treated with 10 mM
TQ for 24 hours. Cells were lysed and equal amounts of proteins were immunoblotted with antibodies against caspase-9, caspase-3 cleaved caspase-
3, PARP and beta-actin. (C) TQ suppresses growth of ABC cells. ABC cell lines were incubated with 0–50 mM TQ for 24 hours. Cell viability was
measured by MTT assays as described in Materials and Methods. The graph displays the mean +/2 SD (standard deviation) of three independent
experiments, * p,0.05, statistically significant (Students t-test). (D) TQ treatment induces apoptosis in ABC cell lines. ABC cells were treated with 5
and 10 mM TQ (as indicated) for 24 hours and cells were subsequently stained with flourescein-conjugated annexin-V and propidium iodide (PI) and
analyzed by flow cytometry.
doi:10.1371/journal.pone.0060540.g005
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DR5 or were it caspases dependent. HBL-1 cell line was either
treated with 10 mM NAC or 80 mM zVAD-fmk for 3 hours
followed by treatment with 10 mM TQ for 24 hours. As shown in
Figure 6B, NAC pre-treatment was able to block TQ-induced up-
regulation of DR5 while caspases inhibitor failed to block DR5 up-
regulation. This data clearly indicated that DR5 up-regulation is
dependent on TQ-induced ROS release in ABC cells.
DR5 up-regulation does not contribute to TQ-induced
apoptosis in ABC cells
DR5, one of the receptors of TRAIL is required for activation of
the extrinsic apoptotic pathway [32], however, it has been
previously been shown that DR5 does not a play a role in TQ-
induced apoptosis [14]. To confirm this, we transiently transfected
HBL-1 and RIVA cells with either scrambled or DR5 targeting
siRNA followed by treatment with TQ for 24 hours. Knock-down
of DR5 expression did not affect the apoptotic response of ABC
cells to TQ treatment as assessed by annexin v/PI dual staining
(Figure 6C) nor did it affect the activation and cleavage of
caspases-8, -3 and PARP (Figure 6D) suggesting that DR5 does
not play a role in TQ-induced apoptosis in ABC cells.
Synergistic activity of TRAIL and TQ to induce apoptosis
in ABC cell lines
Even though DR5 did not play an active role in TQ-induced
apoptosis in ABC cells, it presented as an additional attractive
target for the treatment of ABC cells. We therefore sought to
determine whether co-treatment of TQ and TRAIL, a death
ligand, at sub-optimal doses could induce a more potent apoptosis
in ABC cells. As shown in Table S3 and Figure S3, using Chou
and Talalay method [14,33], we found that 1 mM TQ and 1 ng
super killer TRAIL exerted the maximum synergistic apoptotic
response in HBL-1 cells (combination index 0.359) and RIVA cells
(combination index 0.168) both the values being less than 0.5
suggesting a strong synergistic response[33]. We therefore co-
treated DLBCL cells with 1 mM TQ and 1 nM TRAIL and
assessed cell viability by MTT assay and apoptosis. As shown in
Figure 6E, neither TQ nor TRAIL treatment inhibited cell
viability alone, however, when both the drugs were given in
combination, there was sufficient inhibition of cell viability and
induction of apoptosis (Figure 6F) along with activation and
cleavage of caspases-8, -3 and PARP in ABC cell (Figure 6G).
These data clearly indicate that combination of TQ and TRAIL
efficiently induces apoptosis in ABC cells.
Discussion
Although DLBCL can be morphologically similar, gene
expression profiling has demonstrated molecularly distinct sub-
types with different clinical behavior and outcome[34]. One of the
main factors that is associated with poor prognosis of ABC sub-
type of DLBCL is the constitutive activation of NFkB pathway due
to its ability to block apoptotic response to different chemother-
apeutic agents [35]. Understanding the aetiology of NF-kB
activation can provide a rationale for targeting NF-kB in the
ABC subtype of DLBCL that is characterized by constitutive NF-
kB activation and shows resistance to current therapeutic
modalities. In our earlier study, we had shown nuclear factor
kappa B expression was seen in 25% of DLBCL, was associated
with activated B cell phenotype and poor survival[36]. In the
current study, we found that p-IkB expression is also an
independent prognostic marker for poor survival in ABC subgroup
of DLBCL. Considering the potential prognostic and therapeutic
role of NF-kB, p-IkB can be a promising marker along with NF-kB
in a panel of molecular markers to detect DLBCL with NF-kB
activation.
Our in-vitro studies have shown that panel of ABC cell lines
derived also exhibit constitutive NFkB activity. In this study, we
have investigated the molecular mechanism of NFkB mediated
anti-apoptotic role in ABC cell lines using Thymoquinone (TQ),
an active constituent of black seed that has well-documented pro-
apoptotic properties in a variety of cell types, including cells of
hematopoietic origin [12,13,37,38]. Our study indicates that TQ
treatment inhibits constitutive activation of NFkB suggesting an
important role in inhibiting the growth and viability of ABC in
vitro. By inhibiting the constitutive activity of NFkB, the anti-
apoptotic transcriptional targets of NFkB also get down-regulated
thereby allowing the pro-apoptotic proteins to assert its apoptotic
effects. The anti-apoptotic targets of NFkB, Bcl-2 and Bcl-Xl
belong to Bcl-2 family of proteins and have been shown to exert
their anti-apoptotic effect acting as guardians of mitochondria by
in-activating Bax and Bak, the pro-apoptotic members of the Bcl-2
family [39]. On the other hand, XIAP inhibits apoptosis via
interacting with caspases-9 and -3 thereby inhibiting their
activation [40]. By down-regulating the NFkB activity, TQ
treatment also down-regulates the expression of Bcl-2, Bcl-Xl
and XIAP leading to mitochondrial-induced apoptosis via
activation and cleavage of caspases in ABC cells.
There are studies that have shown that ROS release sensitizes
cancer cells to TRAIL induced apoptosis via up-regulation of DR5
in various cancers [41,42,43,44,45]. We also show that treatment
of ABC cells with TQ causes up-regulation of DR5. Even though,
we find up-regulation of DR5, DR5 alone does not play a role in
TQ-induced apoptosis in ABC cells because, even after knocking
down the expression of DR5 in ABC cells, there was efficient
apoptosis following TQ treatment. However, DR5 up-regulation
following TQ treatment does offer an attractive therapeutic target
for the treatment of ABC cells. We have previously shown that
TQ-induced up-regulation can be targeted with TRAIL to induce
a synergistic apoptotic response in primary effusion lymphoma
cells[14]. In concordance, combination of TQ and TRAIL at sub-
optimal doses induced significant apoptosis as compared to
treatment as a single agent in ABC cells. The benefit of targeting
ABC cells with a combination of TQ and TRAIL is that both the
intrinsic as well as the extrinsic apoptotic pathways can be
activated simultaneously to elicit a more potent apoptotic
response. Another reason of using this combination at sub-optimal
doses is that TRAIL at high concentrations has been found to be
toxic to normal cells of the body [46], however, at sub-optimal
doses, TRAIL does not elicit cytotoxicity towards normal cells
thereby making it an attractive drug to be used in conjunction with
other inhibitors or chemotherapeutic agents.
Treatment of ABC subtype of DLBCL still remains a major
challenge despite improvement in therapy including addition of
Rituximab with CHOP. In this manuscript, we have highlighted a
different mechanism of targeting these aggressive lymphomas.
Targeting of constitutively active survival pathways such as NFkB
with agents such as TQ in cancer allow selective killing of these
aggressive cells with minimal targeting of their normal counter-
parts thereby decreasing the chances of toxicity. Therefore the
cytotoxic inducing ability of TQ in cancer could make it a
potentially effective chemo-preventive and/or therapeutic agent
for the treatment of these lymphomas. In addition, combination
treatment with TQ and TRAIL allows further reduction in the
dosage of these agents thereby improving the response and
decreasing the toxicity. Based on our data, further studies in this
direction are warranted.
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Figure 6. TQ-induced up-regulation of DR5 does not play a part in TQ-induced apoptosis. (A) TQ treatment causes up-regulation of DR5
in ABC cells. HBL1 and RIVA cells were treated with 10 mM TQ for indicated time periods. After cell lysis, equal amounts of proteins were immuno-
blotted with antibodies against DR5 and beta actin. (B) TQ-induced DR5 up-regulation is ROS dependent. HBL-1 cells were pre-treated with either
10 mM NAC or 80 mM z-VAD for 3 hours and subsequently treated with 10 mM TQ for 24 hours. Cells were lysed and equal amounts of proteins were
immunoblotted with antibodies against DR5 and beta-actin. (C and D) TQ-induced apoptosis is not DR5 dependent. (C) HBL-1 and RIVA cells were
either transfected with 50 and 100 nM siRNA, specific against DR5 or scrambled siRNA for 48 hours. Cells were then treated with 5 and 10 mM TQ for
24 hours, following which cells were stained with fluorescent-conjugated Annexin V/PI and analyzed by flow cytometry. Bar graph displays the mean
+/2 SD (standard deviation) of three independent experiments, * p,0.05, statistically significant (Students t-test). (D) HBL-1 and RIVA cells were
either transfected with 50 and 100 nM siRNA, specific against DR5 or scrambled siRNA for 48 hours and treated with 5 and 10 mM TQ for 24 hours.
Cells were lysed and equal amounts of proteins were immuno-blotted with antibodies against DR5, caspase-8, caspase-3, PARP and beta-actin. (E):
Combination treatment with sub-optimal doses of TQ and TRAIL induce synergistic inhibition of cell viability and apoptosis in ABC cells. HBL-1 and
RIVA cells were treated with either 1 mM TQ in the presence and absence of 1 ng TRAIL for 24 hours. Following treatment, cells were analyzed for cell
viability by MTT assay as described in material and methods. Bar graph displays the mean +/2 SD (standard deviation) of three independent
experiments, * p,0.05, statistically significant (Students t-test). (F) HBL-1 and RIVA cells were treated with either 1 mM TQ in the presence and
absence of 1 ng TRAIL for 24 hours. Following treatment, cells were stained with fluorescent-conjugated Annexin V/PI and analyzed by flow
cytometry (G) HBL-1 cells were treated with either 1 mM TQ in the presence and absence of 1 ng TRAIL for 24 hours. Following treatment, cells were
lysed and equal amounts of proteins were immuno-blotted with antibodies against caspase-8, caspase-3, PARP, and beta-actin.
doi:10.1371/journal.pone.0060540.g006
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Supporting Information
Figure S1 TQ inactivated p65 in the nuclear compart-
ment in ABC cells. HBL1 and RIVA cells were treated with 5
and 10 mM TQ for 24 hours. Following treatment, cells were
nuclear extracts were prepared and immunoblotted with antibod-
ies against p-p65 and Alpha-Tubulin for equal loading.
(TIF)
Figure S2 TQ-induced apoptosis is blocked by combi-
nation of catalase and superoxide dismutase (SOD) in
ABC cells. HBL1 and RIVA cells were pre-treated with
100 units/ml catalase, 100 units/ml SOD, combination of
catalase and SOD and NAC for three hours followed by treatment
with 10 mM TQ for 24 hours. Following treatment, cells were
stained with fluorescein-conjugated annexin v/PI and analyzed for
apoptosis by flow cytometry. Bar graph displays the mean +/2 SD
(standard deviation) of three independent experiments.
(TIF)
Figure S3 Synergistic apoptotic response of TQ and
TRAIL in ABC cells. (A and B) HBL-1 and RIVA cells were
treated with various combinations of TQ and TRAIL alone or in
combination for 24 hours and dose effect was measured using
calcusyn software. (C and D) Five different concentrations of TQ
(0.5 to 25 mM) and TRAIL (0.5 to 25 ng) were used together in
different combinations as shown in the Figure C and D (1–5) to
determine the Fractional effect of combination treatment with TQ
and TRAIL and graphs were generated using Calcusyn software.
Apoptotic response were analyzed as mean 6 SD values
normalized to control. Combination indices were calculated using
Chou and Talalay methodology.
(TIF)
Table S1 Antibodies used for tissue micro array
Immunohistochemical analysis. List of antibodies, clones,
dilution, antigen retrieval and detection method used for
immunohistochemistry are indicated in Table S1.
(DOCX)
Table S2 Cox regression analysis for overall survival of
patients with diffuse large B-cell lymphoma –p-IKBa in
ABC Group. Univariate and Multivariate analysis were per-
formed to determine the relative risk and confirm the utility of p-
IKBa as an independent prognostic marker.
(DOCX)
Table S3 Combination index calculation using Chou
and Talalay method in ABC cell lines. HBL1 and RIVA cell
lines were treated with various doses of TQ and TRAIL alone or
in combination and Fraction effect (Fa), Combination Index (CI)
and Dose Reduction Index (DRI) are indicated in Table S3.
(DOCX)
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